Medicus Pharma To Present Pipeline at BIO-Europe
The November 9 Cologne presentation outlines early-stage CD228V and Teverelix programs still in clinical development.
Updated on Nov. 5, 2026 in Biotech
Medicus Pharma Ltd. (NASDAQ: MDCX) will present at BIO-Europe 2026 in Cologne, Germany, on November 9, 2026, from 9:15 to 9:30 a.m. CET in Theatre B at Koelnmesse. The presentation by Chief Medical Officer Dr. Faisal Mehmud will cover precision oncology progress and the partnership outlook for its Teverelix program; all programs discussed are at the investigational or early clinical stage.
Why it matters
The update signals how a small biotech is sequencing its pipeline: CD228V is being pushed toward clinical proof-of-concept in melanoma first, with partnerships sought to supply development resources. Investors and prospective partners will be watching whether the company can convert conference meetings into deals.
The disclosed figures are planning parameters rather than measured outcomes: the Teverelix APC program was originally sized at 1,500 patients and may shrink to 600. No efficacy or safety results for CD228V, SkinJect, or Teverelix were included in the source, so the presentation's technical claims remain unverified.
The players
Medicus Pharma Ltd. (NASDAQ: MDCX)
A Philadelphia-based biotech developing antibody-drug conjugates and next-generation hormone therapies, with CD228V and Teverelix in its pipeline.
Dr. Faisal Mehmud
Chief Medical Officer of Medicus Pharma, who will present the company's precision oncology and Teverelix updates at BIO-Europe 2026.
The details
CD228V is an early clinical-stage antibody-drug conjugate, a therapy that links an antibody to a cytotoxic drug so the antibody can deliver the payload to target cells. Medicus uses Pfizer's vedotin linker-payload platform to attach that drug. The company says it is prioritizing clinical proof-of-concept for CD228V in melanoma, and believes evidence there could support evaluation in other CD228-expressing solid tumors. Teverelix is an investigational next-generation GnRH antagonist, a class of drug that blocks gonadotropin-releasing hormone signaling.
Timeline
November 9, 2026: Dr. Mehmud presents at BIO-Europe 2026, 9:15-9:30 a.m. CET.
November 9-11, 2026: BIO-Europe 2026 runs in Cologne, Germany.
End of 2026: Anticipated completion of GMP-grade manufacturing and clinical readiness steps for Teverelix.
The Tech Race
Medicus is building CD228V on a licensed vedotin linker-payload platform rather than proprietary chemistry, which keeps its early program within a method already used in other antibody-drug conjugate pipelines. The company's stated next step is clinical proof-of-concept in melanoma, the milestone that will determine whether CD228V separates from competing efforts in the field.
The presentation affects participants at BIO-Europe 2026, and Medicus will hold one-on-one meetings with institutional investors and prospective partners throughout the conference. Patients are not affected directly, since CD228V and Teverelix remain investigational and no availability or pricing has been announced.
The takeaway
The melanoma proof-of-concept for CD228V and any partnership announced around BIO-Europe are the concrete milestones to track. Investors can check Medicus's next disclosures against the end-of-2026 Teverelix readiness target.
What happens next
Dr. Mehmud's presentation is scheduled for November 9, 2026, at 9:15 a.m. CET in Cologne, and the company's Teverelix manufacturing and clinical readiness steps are anticipated by the end of 2026.
Further reading
For more on the field behind these programs, see our Biotech coverage of drug development and antibody-drug conjugates.
Source note: This article includes information reported by The Manila times.
